Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $-93M | $-101M | $-97M | -46.0% | -20.3% | 0.3% |
| 2024 | $3M | $-104M | $-101M | $-92M | -46.9% | 182.6% | 5.3% |
| 2023 | $1M | $-107M | $-96M | $-99M | -35.3% | - | -27.5% |
| 2022 | $0M | $-112M | $-132M | $-101M | -36.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 2.44 |
| Operating Revenue | 2.44 |
| Cost Of Revenue | 1.28 |
| Gross Profit | 1.15 |
| Operating Expense | 98.51 |
| Research And Development | 53.76 |
| Selling General And Administration | 44.75 |
| Total Expenses | 99.80 |
| Operating Income | -97.36 |
| Total Operating Income As Reported | -116.10 |
| EBITDA | -92.91 |
| Normalized EBITDA | -79.07 |
| EBIT | -97.36 |
| Interest Income | 8.96 |
| Interest Expense | - |
| Net Interest Income | 8.96 |
| Other Non Operating Income Expenses | 0.96 |
| Other Income Expense | -12.88 |
| Interest Income Non Operating | 8.96 |
| Interest Expense Non Operating | - |
| Net Non Operating Interest Income Expense | 8.96 |
| Pretax Income | -101.28 |
| Tax Provision | 0.06 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -2.91 |
| Net Income Continuous Operations | -101.34 |
| Net Income From Continuing And Discontinued Operation | -101.34 |
| Net Income From Continuing Operation Net Minority Interest | -101.34 |
| Net Income | -101.34 |
| Net Income Common Stockholders | -101.34 |
| Net Income Including Noncontrolling Interests | -101.34 |
| Normalized Income | -90.41 |
| Diluted NI Availto Com Stockholders | -101.34 |
| Basic Average Shares | 197.76 |
| Diluted Average Shares | 197.76 |
| Reconciled Depreciation | 4.45 |
| Reconciled Cost Of Revenue | 1.28 |
| Total Unusual Items | -13.84 |
| Total Unusual Items Excluding Goodwill | -13.84 |
| Special Income Charges | -18.74 |
| Other Special Charges | 18.74 |
| Impairment Of Capital Assets | - |
| Gain On Sale Of Security | 4.90 |
| General And Administrative Expense | - |
| Other Gand A | - |
| Selling And Marketing Expense | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Quantum-Si incorporatedthis co. | QSI | $279M | -2.75 | 1.27 | -46.0% | -2.81 |
| Alpha Teknova, Inc. | TKNO | $291M | -16.87 | 4.23 | -25.1% | -30.89 |
| OraSure Technologies, Inc. | OSUR | $287M | -4.18 | 0.84 | -20.2% | -1.74 |
| Niagen Bioscience, Inc. | NAGE | $279M | 16.04 | 3.64 | 22.7% | 13.78 |
| Eledon Pharmaceuticals, Inc. | ELDN |
| - |
| - |
| - |
| - |
| - |
| $278M |
| -6.09 |
| 3.43 |
| -56.3% |
| -3.08 |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M | -1.89 | 1.24 | -65.8% | -2.14 |
| Peer Median | - | -4.91 | 3.09 | -36.0% | -1.74 | |